Home » Topics » BioWorld Science, Neurology/psychiatric

BioWorld Science, Neurology/psychiatric
RSS

Lundbeck discovers phosphodiesterase PDE1 inhibitors

July 9, 2019

Novel rat model of multiple system atrophy unresponsive to L-dopa

July 9, 2019

Intra-Cellular Therapies reports topline phase III data on lumateperone in bipolar depression

July 8, 2019

TDP-43 screen identifies potential therapeutics for ALS and frontotemporal dementia

July 8, 2019

Gedeon Richter presents vasopressin V1A receptor antagonists

July 8, 2019

Chaperone gene therapy delays ALS

July 8, 2019

Tau-targeted PET with flortaucipir in Alzheimer's disease: evaluation of tau and cognitive changes

July 8, 2019

Lasmiditan for acute treatment of migraine: results from phase III trial

July 5, 2019

Aquaporin-1 is a potential therapeutic target in TBI, researchers find

July 5, 2019

Viral-MS link comes via bad memories

July 5, 2019

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for May 22, 2026.
‘Detargeted’ targeted gene therapy improves activity in Pompe
BioWorld
A new strategy aims to improve gene therapy for Pompe disease by optimizing both the genetic component that restores the function of a deficient lysosomal enzyme...
Roche reports new TREM2 agonists
BioWorld Science
F. Hoffmann-la Roche Ltd. and Hoffmann-La Roche Inc. have identified new triggering receptor expressed on myeloid cells 2 (TREM2) agonists potentially useful for...
Genescience presents STAT6 degrader for atopic dermatitis
BioWorld Science
Genescience Pharmaceutical Co. Ltd. has presented data on a new STAT6 PROTAC degrader – GenSciP166 – which selectively targets STAT6 for proteasomal degradation....
Sangamo presents primate data for prion suppressor ST-506
BioWorld Science
Sangamo Therapeutics Inc. discussed gene regulation approaches for neurodegenerative diseases when presenting findings on their clinical candidate ST-506 for the...